Tag : Corporate Ugliness

Home/Posts Tagged" Corporate Ugliness" (Page 4)

Monsanto a Focus of US Antitrust Investigation


original link: www.npr.org
ST. LOUIS October 8, 2009 (AP)

The Justice Department is investigating whether Monsanto Co. violated antitrust rules in trying to expand its dominance of the market for genetically engineered crops.

Monsanto has provided interviews and documents to the Justice Department, company spokesman Lee Quarles said. He said the department has questioned Monsanto about its marketing tactics in the biotech seed industry, which have become a target of criticism.

Quarles said Monsanto has done nothing illegal and is cooperating with the department.

“We definitely stand behind our business,” he said.

At issue is how the world’s largest seed company sells and licenses its patented genes. Monsanto has licensing agreements with seed companies that let those companies insert Monsanto genes into about 96 percent of U.S. soybean crops and 80 percent of all corn crops.

Monsanto’s rivals allege that the company uses the licensing agreements to squeeze competitors and control smaller seed companies — an allegation Monsanto denies.

The inquiry into St. Louis-based Monsanto is part of a previously announced Justice Department investigation of consolidation in the seed industry.

A department spokeswoman declined to confirm or deny the investigation. But the department has interviewed two of Monsanto’s biggest rivals, Delaware-based DuPont and Swiss biotech firm Syngenta AG, about Monsanto’s business practices. Both companies said they are cooperating with the probe.

Continue Reading

Walmart’s $4 Drugs Coming From Indian Company Whose Products Have Been Banned In US and Canada

A New Report from WakeUpWalMart.com WakeupWalmart.com supports the use of generic prescription drugs as a safe alternative to expensive, name-brand medications. Walmart's use of a corporate bad actor to cut costs, however, deserves significant scrutiny. Walmart is heavily promoting a program of 30-day supplies of generic drugs for $4, pointing to
Continue Reading